Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Disease-Free Survival In Renal Cancer Raises Questions, But Still Acceptable, ODAC Says

Sep 21 2017

• By Derrick Gingery

Puzzle

Related Content

Pfizer v. Pfizer: Sutent Indication Expansion Will Hinge On Conflicting Trials

Sep 17 2017

Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

Sep 20 2017

Pfizer Sutent Label Expansion May Hinge On Disease-Free Survival Stats

Sep 10 2017

Related Companies

Pfizer Inc.

Additional Topics

United States Advisory Committees Clinical Trials Drug Approval Standards Drug Review Regulation Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window